1. Introduction
===============

Soft corals have proven to be a rich source of terpenoids \[[@B1-marinedrugs-10-00439]\]. We previously have isolated a series of bioactive cembrane- \[[@B2-marinedrugs-10-00439],[@B3-marinedrugs-10-00439],[@B4-marinedrugs-10-00439]\] and norcembrane- \[[@B5-marinedrugs-10-00439],[@B6-marinedrugs-10-00439],[@B7-marinedrugs-10-00439],[@B8-marinedrugs-10-00439]\] diterpenoids from the Formosan soft corals of the genus *Sinularia.* Previous chemical investigations on the soft coral *Sinularia crassa* have led to the isolation of structurally unique steroids and cembranoids, from which some have been shown to exhibit anti-inflammatory \[[@B9-marinedrugs-10-00439],[@B10-marinedrugs-10-00439]\] and 5α-reductase inhibitory activities \[[@B11-marinedrugs-10-00439]\], respectively. Our continuing chemical investigation on *S. crassa* has led to the isolation of one new sterol, crassarosterol A (**1**), and four new steroidal glycosides, crassarosterosides A--D (**2**--**5**) ([Figure 1](#marinedrugs-10-00439-f001){ref-type="fig"}). The structures of **1**--**5** have been established by extensive spectroscopic analysis, including 2D NMR (^1^H--^1^H COSY, HMQC, HMBC, and NOESY), chemical methods, and HPLC. The effect of **1**--**4** on the expression of the pro-inflammatory inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage cells and the cytotoxicity of compounds **1**--**5** against a panel of cancer cell lines including human liver carcinoma (HepG2 and HepG3), human breast carcinoma (MCF-7 and MDA-MB-231), and human lung carcinoma (A-549) were evaluated in order to discover bioactive natural products.

![Structures of compounds **1**--**5**.](marinedrugs-10-00439-g001){#marinedrugs-10-00439-f001}

2. Results and Discussion
=========================

The HRESIMS of crassarosterol A (**1**) exhibited a pseudomolecular ion peak at *m/z* 453.3342 \[M + Na\]^+^, consistent with a molecular formula of C~28~H~46~O~3~ and requiring six degrees of unsaturation. The ^13^C NMR and DEPT spectroscopic data ([Table 1](#marinedrugs-10-00439-t001){ref-type="table"}) displayed 28 carbon signals, including five methyls, nine methylenes, ten methines, and four quaternary carbons. The IR spectrum revealed the presence of hydroxy groups (3389 cm^--1^). The carbon resonances at *δ* 141.2 (C), 121.3 (CH), 156.9 (C), and 106.3 (CH~2~) suggested the presence of two double bonds. The above data coupled with the characteristic ^1^H NMR signals for methyl groups at *δ* 0.92 (3H, s), 1.18 (3H, s), 1.04 (3H, d, *J* = 6.8 Hz), and 1.03 (6H, d, *J* = 7.2 Hz) and signals for olefinic protons at *δ*~H~ 5.41 (1H, d, *J* = 5.6 Hz), 4.76 (1H, s), and 4.70 (1H, s) ([Table 2](#marinedrugs-10-00439-t002){ref-type="table"}) suggested **1** to be a member of the 24-methylenecholesterol class \[[@B12-marinedrugs-10-00439],[@B13-marinedrugs-10-00439]\]. The ^1^H−^1^H COSY correlations allowed the assignment of four separated spin systems ([Figure 2](#marinedrugs-10-00439-f002){ref-type="fig"}). The presence of an sp^2^ methylene substituent at C-24 was further confirmed by the HMBC correlations from H~2~-28 to C-23, C-24, and C-25 ([Figure 2](#marinedrugs-10-00439-f002){ref-type="fig"}). Likewise, the steroidal nucleus was confirmed by the HMBC correlations from H~3~-18 to C-12, C-13, C-14, and C-17 and H~3~-19 to C-1, C-5, C-9, and C-10. The NOE correlations between H~3~-19/H-1β, H-3/H-1α, and H~3~-19/H-11 suggested the α and β orientations for H-3 and H-11, respectively. The absence of an NOE correlation between H~3~-18/H-17 and the presence of the correlation between H-17/H-16, H-16/H-14, and H-14/H-9 suggested the α orientation for H-9, H-14, H-16, and H-17. Moreover, the β orientation for H-20 was evidenced from the NOE correlations between H~3~-18/H-20, H~3~-18/H-12a, and H~3~-21/H-12a. The absolute configuration of **1** was determined by the application of Mosher's method \[[@B14-marinedrugs-10-00439]\]. Analysis of the ^1^H NMR data of esters **1a** and **1b** resulted in the determination of a 3*S* configuration ([Figure 3](#marinedrugs-10-00439-f003){ref-type="fig"}).

marinedrugs-10-00439-t001_Table 1

###### 

^13^C NMR spectroscopic data of compounds **1**−**5**.

  position   1*^a^*         2*^b^*         3*^b^*         4*^a^*         5*^a^*
  ---------- -------------- -------------- -------------- -------------- -------------
  1          39.1, CH~2~    39.2, CH~2~    39.2, CH~2~    39.2, CH~2~    37.1, CH~2~
  2          31.8, CH~2~    29.7, CH~2~    29.5, CH~2~    29.7, CH~2~    29.6, CH~2~
  3          71.8, CH       78.2, CH       77.8, CH       78.2, CH       78.3, CH
  4          42.7, CH~2~    39.1, CH~2~    39.0, CH~2~    39.1, CH~2~    38.8, CH~2~
  5          141.2, C       140.6, C       140.7, C       140.5, C       140.3, C
  6          121.3, CH      121.7, CH      121.6, CH      121.8, CH      122.1, CH
  7          31.9, CH~2~    31.8, CH~2~    31.8, CH~2~    31.8, CH~2~    31.5, CH~2~
  8          31.4, CH       31.3, CH       31.3, CH       31.3, CH       30.4, CH
  9          56.9, CH       56.8, CH       56.9, CH       56.8, CH       50.3, CH
  10         38.1, C        38.3, C        38.3, C        38.3, C        36.9, C
  11         68.9, CH       68.9, CH       68.9, CH       68.9, CH       21.0, CH~2~
  12         51.4, CH~2~    51.4, CH~2~    51.4, CH~2~    51.4, CH~2~    36.2, CH~2~
  13         42.9, C        42.9, C        42.9, C        42.9, C        47.4, C
  14         53.7, CH       53.6, CH       53.6, CH       53.6, CH       57.9, CH
  15         36.3, CH~2~    36.3, CH~2~    36.3, CH~2~    36.3, CH~2~    31.0, CH~2~
  16         72.5, CH       72.5, CH       72.5, CH       72.5, CH       123.8, CH
  17         61.2, CH       61.2, CH       61.2, CH       61.2, CH       160.9, CH
  18         14.0, CH~3~    14.1, CH~3~    14.1, CH~3~    14.1, CH~3~    18.1, CH~3~
  19         19.1, CH~3~    19.0, CH~3~    19.0, CH~3~    19.0, CH~3~    19.3, CH~3~
  20         29.6, CH       29.6, CH       29.6, CH       29.6, CH       76.0, C
  21         18.2, CH~3~    18.2, CH~3~    18.2, CH~3~    18.2, CH~3~    29.6, CH~3~
  22         34.8, CH~2~    34.8, CH~2~    34.7, CH~2~    34.7, CH~2~    49.1, CH~2~
  23         31.2, CH~2~    31.2, CH~2~    31.2, CH~2~    31.2, CH~2~    29.6, CH
  24         156.9, C       156.9, C       156.9, C       156.9, C       45.5, CH
  25         34.1, CH       34.0, CH       34.0, CH       34.0, CH       30.9, CH
  26         21.8, CH~3~    21.8, CH~3~    21.8, CH~3~    21.8, CH~3~    20.9, CH~3~
  27         21.9, CH~3~    21.9, CH~3~    21.9, CH~3~    21.9, CH~3~    21.5, CH~3~
  28         106.3, CH~2~   106.3, CH~2~   106.3, CH~2~   106.4, CH~2~   11.6, CH~3~
  29                                                                     15.7, CH~3~
  1'                        97.4, CH       94.7, CH       97.2, CH       97.2, CH
  2'                        74.0, CH       68.6, CH       70.1, CH       70.1, CH
  3'                        66.9, CH       72.1, CH       69.5, CH       69.5, CH
  4'                        70.9, CH       72.4, CH       73.0, CH       73.0, CH
  5'                        65.8, CH       65.3, CH       65.2, CH       65.2, CH
  6'                        16.0, CH~3~    16.1, CH~3~    16.2, CH~3~    16.2, CH~3~
  OAc                       170.9, C       171.5, C       171.3, C       171.3, C
                            21.2, CH~3~    21.1, CH~3~    20.8, CH~3~    20.8, CH~3~

*^a^* Spectra were measured in CDCl~3~ (100 MHz); *^b^* Spectra were measured in CDCl~3~ (125 MHz).

![Selected ^1^H−^1^H COSY (▬) and HMBC (→) correlations of **1** and **5** and the fucose residue in **1**--**5**.](marinedrugs-10-00439-g002){#marinedrugs-10-00439-f002}

Analysis of the HRESIMS and ^13^C NMR spectroscopic data of crassarosteroside A (**2**) suggested a molecular formula of C~36~H~58~O~8~. The IR spectrum of **2** showed the presence of hydroxy (3461 cm^−1^) and carbonyl (1741 cm^−1^) groups. The latter was identified as an acetoxy group according to the carbon resonances at *δ* 170.9 (C) and 21.2 (CH~3~) ([Table 1](#marinedrugs-10-00439-t001){ref-type="table"}). The ^1^H NMR spectroscopic data of **2** showed characteristic methyl signals at *δ* 0.92 (3H, s), 1.18 (3H, s), 1.04 (3H, d, *J* = 6.8 Hz), 1.03 (6H, d, *J* = 7.0 Hz), 5.41 (1H, d, *J* = 5.6 Hz), 4.76 (1H, s), and 4.70 (1H, s) ([Table 2](#marinedrugs-10-00439-t002){ref-type="table"}), revealing that **2** has the same 24-methylenecholesterol skeleton as that of **1**. By excluding the steroidal moiety and the acetoxy group, the remaining six carbons \[δ 97.4 (CH), 74.0 (CH), 66.9 (CH), 70.9 (CH), 65.8 (CH), and 16.0 (CH~3~)\] were ascribed to the presence of a 6'-deoxyhexose residue. The sugar residue was deduced as an α-fucopyranose on the basis of 2D NMR analysis ([Figure 2](#marinedrugs-10-00439-f002){ref-type="fig"}) and the coupling constants of ^3^*J*~H-1',H-2'~ (4.0 Hz), ^3^*J*~H-2',H-3'~ (10.0 Hz), ^3^*J*~H-3',H-4'~ (3.5 Hz), and ^3^*J*~H-4',H-5'~ (\<1 Hz) ([Table 2](#marinedrugs-10-00439-t002){ref-type="table"}) \[[@B12-marinedrugs-10-00439],[@B15-marinedrugs-10-00439],[@B16-marinedrugs-10-00439]\]. The acetoxy group attached at C-2' of the α-fucose residue was evidenced from the downfield chemical shift of H-2' (*δ* 5.07), which was confirmed by the HMBC correlations from this proton to the acetate carbonyl carbon. The HMBC correlation from H-1' to C-3 revealed that the α-fucose residue was attached at C-3 of the steroidal aglycone. The absolute configuration of the sugar moiety in **2** was determined by reversed phase HPLC analysis of its *o*-tolylthiocarbamate \[[@B17-marinedrugs-10-00439]\]. The liberated fucose from acid hydrolysis of **2** was treated with [L]{.smallcaps}-cysteine methyl ester followed by reaction with *o*-tolylisothiocyanate to afford the corresponding *o*-tolylthiocarbamate derivative. The retention time of the liberated sugar derivative by HPLC analysis was found to be consistent with that of a standard [L]{.smallcaps}-fucose derivative.

Crassarosteroside B (**3**) gave the same molecular formula as that of **2** based on the analysis of the HRESIMS and ^13^C NMR spectroscopic data ([Table 1](#marinedrugs-10-00439-t001){ref-type="table"}). The NMR spectroscopic data of **3** were similar to those of **2**, with some exceptions for those of the sugar residue. An HMBC correlation from the anomeric proton at *δ* 5.12 (H-1') to the carbon signal at *δ* 77.8 (C-3) connected the fucose residue to C-3 of the steroidal aglycone. The downfield proton chemical shift at *δ* 4.87 (1H, dd, *J* = 10.5, 4.0 Hz) was ascribed to the presence of an acetoxy group at C-3' ([Table 2](#marinedrugs-10-00439-t002){ref-type="table"}). The detailed 2D NMR analysis confirmed the above elucidation. Likewise, the [L]{.smallcaps}-fucose residue was deduced according to RP HPLC analysis of the corresponding *o*-tolylthiocarbamate as described above.

![^1^H NMR chemical shift differences of MTPA esters of **1**.](marinedrugs-10-00439-g003){#marinedrugs-10-00439-f003}

Crassarosteroside C (**4**) was assigned the same molecular formula as those of **2** and **3**. A comparison of NMR spectroscopic data of **4** with those of **2** and **3** revealed that an acetoxy group should be located at C-4' of the fucose residue ([Table 1](#marinedrugs-10-00439-t001){ref-type="table"} and [Table 2](#marinedrugs-10-00439-t002){ref-type="table"}). This was evidenced by the ^1^H NMR shift of H-4' at 5.20 (1H, d, *J* = 2.8 Hz). In the same manner, RP HPLC anslysis of the corresponding *o*-tolylthiocarbamate derived from the hydrolyte of **4** allowed the determination of the [L]{.smallcaps}-fucose moiety.

The HRESIMS and ^13^C NMR spectroscopic data of crassarosteroside D (**5**) established a molecular formula of C~37~H~60~O~7~. The presence of an acetoxy group was evidenced by the ^1^H NMR signal at δ 2.17 (3H, s) ([Table 1](#marinedrugs-10-00439-t001){ref-type="table"}) and ^13^C NMR signals at δ 171.3 (C) and 20.8 (CH~3~) ([Table 2](#marinedrugs-10-00439-t002){ref-type="table"}) as well as the IR absorption band at 1737 cm^−1^. The NMR spectroscopic data for the sugar moiety of **5** were quite similar to those of **4**, suggesting that they shared the same 4'-*O*-acetylfucose residue. Except for the sugar moiety, the remaining 29 carbon signals as well as the characteristic methyl signals at *δ* 1.00 (3H, s), 1.05 (3H, s), 1.38 (3H, s), 0.86 (3H, d, *J* = 6.4 Hz), 0.89 (3H, d, *J* = 6.4 Hz), 0.76 (3H, d, *J* = 6.8 Hz), and 0.78 (3H, d, *J* = 6.4 Hz) ([Table 2](#marinedrugs-10-00439-t002){ref-type="table"}) revealed that the aglycone of **5** should have a C~29~ steroidal skeleton \[[@B18-marinedrugs-10-00439]\]. The 23,24-dimethyl-20-hydroxy side chain was deduced by the ^1^H−^1^H COSY correlations from H~2~-22 to H~3~-29 through H-23, from H-24 to both H~3~-26 and H~3~-27, and from H-24 to H~3~-28 as well as the HMBC correlations from H~3~-21 to C-17, C-20, and C-22 and H~3~-29 to C-22, C-23, and C-24. This rare steroidal side chain is the same as that of sarcophytosterol isolated previously by us from the soft coral *Lobophytum sarcophytoides* \[[@B18-marinedrugs-10-00439]\]. The NMR spectroscopic data for the aglycone moiety of **5** are almost the same as those of sarcophytosterol, except for some minor variations in ^1^H and ^13^C chemical shifts at C-2, C-3, and C-4 between both compounds. This is due to the attachment of the sugar residue at C-3 of the steroidal aglycone. Similarly, HPLC analysis of the relevant *o*-tolylthiocarbamate derived from the hydrolysis of **5** suggested the presence of [L]{.smallcaps}-fucose.

marinedrugs-10-00439-t002_Table 2

###### 

^1^H NMR spectroscopic data of compounds **1**−**5**.

  ＃      1, *δ*~H~ (*J* in Hz)*^a^*   2, *δ*~H~ (*J* in Hz)*^b^*   3, *δ*~H~ (*J* in Hz)*^b^*   4, *δ*~H~ (*J* in Hz)*^a^*   5, *δ*~H~ (*J* in Hz)*^a^*
  ------- ---------------------------- ---------------------------- ---------------------------- ---------------------------- ----------------------------
  1       a: 2.55, dt                  a: 2.58, dt                  a: 2.56, dt                  a: 2.58, dt                  a: 1.86, m
          (13.6, 3.6)                  (13.5, 3.5)                  (13.5, 3.5)                  (14.0, 3.6)                  
          b: 1.16, m                   b: 1.16, m                   b: 1.16, m                   b: 1.16, m                   b: 1.10, m
  2       a: 1.81, m                   a: 1.85, m                   a: 1.79, m                   a: 1.81, m                   a: 1.89, m
          b: 1.58, m                   b: 1.65, m                   b: 1.66, m                   b: 1.64, m                   b: 1.60, m
  3       3.53, m                      3.51, m                      3.43, m                      3.49, m                      3.49, m
  4       a: 2.30, m                   a: 2.36, m                   2.24, m                      a: 2.36, m                   a: 2.36, m
          b: 2.26, m                   b: 2.26, m                                                b: 2.26, m                   b: 2.24, m
  6       5.41, d (5.6)                5.41, d (5.5)                5.40, d (5.5)                5.41, d (5.6)                5.38, br d (3.2)
  7       a: 1.99, m                   a: 1.99, m                   a: 1.98, m                   a: 1.99, m                   a: 2.01, m
          b: 1.54, m                   b: 1.56, m                   b: 1.54, m                   b: 1.54, m                   b: 1.61, m
  8       1.50, m                      1.50, m                      1.49, m                      1.50, m                      1.66, m
  9       0.99, m                      0.99, m                      0.97, m                      0.98, m                      1.01, m
  11      4.07, td                     4.07, m                      4.06, m                      4.07, td                     1.59, m
          (10.8, 4.8)                  (10.8, 4.4)                                                                            
  12      a: 2.31, m                   a: 2.31, m                   a: 2.31, m                   a: 2.31, m                   a: 2.10, m
          b: 1.18, m                   b: 1.18, m                   b: 1.18, m                   b: 1.18, m                   b: 1.59, m
  14      0.98, m                      0.98, m                      0.98, m                      0.98, m                      1.41, m
  15      a: 2.24, m                   a: 2.24, m                   a: 2.23, m                   a: 2.23, m                   a: 2.08, m
          b: 1.17, m                   b: 1.16, m                   b: 1.17, m                   b: 1.16, m                   b: 1.87, m
  16      4.40, m                      4.40, m                      4.40, m                      4.40, m                      5.50, br s
  17      1.07, m                      1.07, m                      1.07, m                      1.07, m                      
  18      0.92, s                      0.92, s                      0.92, s                      0.92, s                      1.00, s
  19      1.18, s                      1.18, s                      1.17, s                      1.18, s                      1.05, s
  20      1.86, m                      1.86, m                      1.86, m                      1.87, m                      
  21      1.04, d (6.8)                1.04, d (6.8)                1.04, d (6.5)                1.04, d (6.4)                1.38, s
  22      a: 1.68, m                   a: 1.68, m                   a: 1.68, m                   a: 1.67, m                   a: 1.59, m
          b: 1.22, m                   b: 1.22, m                   b: 1.22, m                   b: 1.22, m                   b: 1.48, m
  23      a: 2.18, m                   a: 2.18, m                   a: 2.18, m                   a: 2.18, m                   1.82, m
          b: 1.95, m                   b: 1.95, m                   b: 1.95, m                   b: 1.95, m                   
  24                                                                                                                          1.06, m
  25      2.24, m                      2.25, m                      2.25, m                      2.25, m                      1.42, m
  26      1.03, d (7.2)                1.03, d (7.0)                1.03, d (7.0)                1.03, d (6.8)                0.86, d (6.4)
  27      1.03, d (7.2)                1.03, d (7.0)                1.03, d (7.0)                1.03, d (6.8)                0.89, d (6.4)
  28      a: 4.76, s                   a: 4.76, s                   a: 4.76, s                   a: 4.76, s                   0.76, d (6.8)
          b: 4.70, s                   b: 4.70, s                   b: 4.70, s                   b: 4.70, s                   
  29                                                                                                                          0.78, d (7.2)
  1'                                   5.02, d (4.0)                5.12, d (4.0)                5.04, d (4.0)                5.04, d (4.0)
  2'                                   5.07, dd (10.0, 4.0)         4.02, m                      3.93, dd (10.0, 4.0)         3.93, dd (10.0, 4.0)
  3'                                   3.91, ddd (11.5,10.0, 3.5)   4.87, dd (10.5, 4.0)         3.74, br d (10.0)            3.74, dd (10.0, 2.4)
  4'                                   3.84, br s                   3.82, br s                   5.20, d (2.8)                5.21, d (2.4)
  5'                                   4.11, q (7.0)                4.12, q (6.5)                4.12, q (6.4)                4.12, q (6.4)
  6'                                   1.25, d (7.0)                1.27, d (6.5)                1.13, d (6.4)                1.14, d (6.4)
  OAc                                  2.18, s                      2.15, s                      2.17, s                      2.17, s
  3'-OH                                1.90, d (11.5)                                                                         
  4'-OH                                1.89, br s                   2.18, br s                                                

*^a^* Spectra were measured in CDCl~3~ (400 MHz); *^b^* Spectra were measured in CDCl~3~ (500 MHz).

![Effect of compounds **1**--**4** at 10 μM on the LPS-induced pro-inflammatory iNOS and on COX-2 protein expression of RAW264.7 macrophage cells by immunoblot analysis. (**A**) Immunoblots for iNOS and *β*-actin, and relative density of iNOS. (**B**) Immunoblots for COX-2 and *β*-actin, and relative density of COX-2. The values are means ± SEM (*n* = 6). The relative intensity of the LPS alone stimulated group was taken as 100%. Under the same experimental conditions, 10 μM CAPE (caffeic acid phenethyl ester; Sigma Chemical Company, St. Louis, MO) reduced the levels of the iNOS and COX-2 protein to 0.8 ± 4.5% and 75.6 ± 12.2%, respectively, relative to the control cells stimulated with LPS. \*Significantly different from LPS alone stimulated group (\**P* \< 0.05).](marinedrugs-10-00439-g004){#marinedrugs-10-00439-f004}

The absolute configuration of sterol **1** has been established by Mosher's method in the present work. On the basis of biogenesis, the steroidal moieties of the glycosides **2**--**5** should possess the same absolute configurations as shown in the formulae. Cytotoxicity of steroids **1**--**5** against HepG2, HepG3, MCF-7, MDA-MB-231, and A-549 cancer cell lines was evaluated. The results showed that **1** exhibited cytotoxicity toward HepG2 cancer cell line with an IC~50~ value of 14.9 µM, while **4** also showed cytotoxicity toward HepG2 and HepG3 cell lines with IC~50~ values of 17.6 and 18.9 µM, respectively. The other compounds were found to be inactive (IC~50~ \> 20 μM) toward the above cancer cell lines after 72 h exposure. The effect of steroids **1**--**4** on the expression of pro-inflammatory iNOS and COX-2 proteins in RAW264.7 macrophage cells stimulated with LPS was also evaluated using immunoblot analysis. At a concentration of 10 µM ([Figure 4](#marinedrugs-10-00439-f004){ref-type="fig"}), steroid **2** was found to significantly reduce the level of iNOS protein to 12.9 ± 4.3% and **4** could reduce the iNOS espression to 50.1 ± 6.3%. However, these compounds could not effectively reduce the level of COX-2. On the contrary, **1**--**3** were found to stimulate the expression of COX-2.

3. Experimental Section
=======================

3.1. General Experimental Procedures
------------------------------------

The melting point was determined using a Fisher-Johns melting point apparatus. Optical rotations were determined with a JASCO P1020 digital polarimeter. IR spectrum was obtained on a JASCO FT/IR-4100 spectrophotometer. The NMR spectra were recorded on a Varian 400 MR NMR or Varian Unity INOVA 500 FT-NMR instrument at 400 or 500 MHz for ^1^H (referenced to TMS, *δ*~H~ 0.00 ppm for CDCl~3~) and 100 or 125 MHz for ^13^C (referenced to *δ*~C~ 77.0 for CDCl~3~). ESIMS and HRESIMS were recorded by ESI FT-MS on a Bruker APEX II mass spectrometer. Silica gel 60 (Merck, 230−400 mesh) and LiChroprep RP-18 (Merck, 40--63 μm) were used for column chromatography. Precoated silica gel plates (Merck, Kieselgel 60 F~254~, 0.25 mm) and precoated RP-18 F~254S~ plates (Merck, 1.05560) were used for TLC analyses. High-performance liquid chromatography (HPLC) was performed on a Hitachi L-7100 pump equipped with a Hitachi L-7400 UV detector at 210 nm and a semi-preparative reversed-phase column (Merck, Hibar Purospher RP-18e, 5 μm, 250 × 10 mm).

3.2. Animal Material
--------------------

The soft coral *Sinularia* *crassa* was collected by hand using scuba off the coast of Sansiantai, Taitung county, Taiwan, in July 2008, at a depth of 10 m, and was stored in a freezer. This soft coral was identified by one of the authors (C.-F.D.). A voucher specimen (specimen no. SST-03) was deposited in the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.

3.3. Extraction and Isolation
-----------------------------

The frozen bodies of *S. crassa* (1.1 kg fresh wt) were minced and extracted with EtOH (3 × 2 L). The organic extract was concentrated to an aqueous suspension and was further partitioned between EtOAc and H~2~O. The EtOAc extract (17.0 g) was fractionated by open column chromatography on silica gel using *n*-hexane--EtOAc and EtOAc--MeOH mixtures of increasing polarity to yield 32 fractions. Fractions 25, eluting with EtOAc--MeOH (8:1), was further separated by silica gel column chromatography with gradient elution (*n*-hexane--acetone, 8:1 to 2:1) to yield four subfractions (25A--25D). Subfraction 25B was subjected to RP-18 column chromatography (MeOH--H~2~O, gradient, 50--90%), and subsequently purified by RP-18 HPLC (CH~3~CN--H~2~O, 65%) to obtain compounds **1** (6.6 mg) and **5** (1.2 mg). Compound **4** (1.8 mg) was obtained from subfraction 25C using RP-18 HPLC (CH~3~CN--H~2~O, 65%). In the same manner, Subfraction 25D was fractionated over RP-18 gel using gradient elution (MeOH--H~2~O, gradient, 50--90%) to yield two subfractions (25D-1 and 25D-2). Subfraction 25D-2 was separated by RP-18 HPLC (CH~3~CN--H~2~O, 85%) to yield compounds **2** (1.8 mg) and **3** (1.6 mg).

Crassarosterol A (**1**): white powder; \[α\]^24^~D~ −45 (*c* 0.66, CHCl~3~); IR (KBr) *v*~max~ 3389, 2962, 2925, 2854, 1462, 1048, 1024 cm^−1^; ^13^C NMR and ^1^H NMR data, see [Table 1](#marinedrugs-10-00439-t001){ref-type="table"} and [Table 2](#marinedrugs-10-00439-t002){ref-type="table"}; ESIMS *m/z* 453 \[M + Na\]^+^; HRESIMS *m/z* 453.3342 \[M + Na\]^+^ (calcd for C~28~H~46~O~3~Na, 453.3344).

Crassarosteroside A (**2**): white powder; \[α\]^24^~D~−34 (*c* 0.18, CHCl~3~); IR (KBr) *v*~max~ 3461, 2960, 2928, 2868, 1741, 1467, 1377, 1244, 1077, 1030 cm^−1^; ^13^C NMR and ^1^H NMR data, see [Table 1](#marinedrugs-10-00439-t001){ref-type="table"} and [Table 2](#marinedrugs-10-00439-t002){ref-type="table"}; ESIMS *m/z* 641 \[M + Na\]^+^; HRESIMS *m/z* 641.4027 \[M + Na\]^+^ (calcd for C~36~H~58~O~8~Na, 641.4029).

Crassarosteroside B (**3**): white powder; \[α\]^24^~D~−17 (*c* 0.16, CHCl~3~); IR (KBr) *v*~max~ 3388, 2963, 2930, 2857, 1732, 1458, 1375, 1258, 1041 cm^−1^; ^13^C NMR and ^1^H NMR data, see [Table 1](#marinedrugs-10-00439-t001){ref-type="table"} and [Table 2](#marinedrugs-10-00439-t002){ref-type="table"}; ESIMS *m/z* 641 \[M + Na\]^+^; HRESIMS *m/z* 641.4026 \[M + Na\]^+^ (calcd for C~36~H~58~O~8~Na, 641.4029).

Crassarosteroside C (**4**): white powder; \[α\]^24^~D~−52 (*c* 0.18, CHCl~3~); IR (KBr) *v*~max~ 3426, 2960, 2930, 2859, 1735, 1461, 1375, 1247, 1074, 1033 cm^−1^; ^13^C NMR and ^1^H NMR data, see [Table 1](#marinedrugs-10-00439-t001){ref-type="table"} and [Table 2](#marinedrugs-10-00439-t002){ref-type="table"}; ESIMS *m/z* 641 \[M + Na\]^+^; HRESIMS *m/z* 641.4026 \[M + Na\]^+^ (calcd for C~36~H~58~O~8~Na, 641.4029).

Crassarosteroside D (**5**): white powder; \[α\]^24^~D~−45 (*c* 0.12, CHCl~3~); IR (KBr) *v*~max~ 3440, 2960, 2925, 2855, 1737, 1461, 1377, 1244, 1074, 1036 cm^−1^; ^13^C NMR and ^1^H NMR data, see [Table 1](#marinedrugs-10-00439-t001){ref-type="table"} and [Table 2](#marinedrugs-10-00439-t002){ref-type="table"}; ESIMS *m/z* 639 \[M + Na\]^+^; HRESIMS *m/z* 639.4234 \[M + Na\]^+^ (calcd for C~37~H~60~O~7~Na, 639.4237).

3.4. Preparation of (***S***)-and (***R***)-MTPA Esters of ***1***
------------------------------------------------------------------

To a solution of **1** (1.0 mg) in pyridine (0.4 mL) was added (*R*)**-**MTPA chloride (25 μL), and the mixture was allowed to stand for 3 h at room temperature. The reaction was quenched by the addition of 1.0 mL of H~2~O, and the mixture was subsequently extracted with EtOAc (3 × 1.0 mL). The EtOAc layers were combined, dried over anhydrous MgSO~4~, and evaporated. The residue was subjected to short silica gel column chromatography using *n*-hexane−EtOAc (3:1) to yield the (*S*)-MTPA ester, **1a** (0.7 mg). The same procedure was used to prepare the (*R*)-MTPA ester, **1b** (1.0 mg from 1.0 mg of **1**), with (*S*)-MTPA chloride. Selected ^1^H NMR (CDCl~3~, 400 MHz) of **1a**: δ 7.41−7.52 (5H, m, Ph), 5.48 (1H, br d, *J* = 6.0 Hz, H-6), 4.89 (1H, m, H-3), 4.76 (1H, s, H-28a), 4.70 (1H, s, H-28b), 4.41 (1H, m, H-16), 4.05 (1H, m, H-11), 3.57 (3H, s, O*Me*), 2.62 (1H, br d, *J* = 14.0 Hz, H-1a), 2.48 (1H, m, H-4a), 1.85 (1H, m, H-2a), 1.17 (3H, s, H~3~-19), 1.03 (6H, d, *J* = 7.2 Hz, H~3~-26 and 27), 0.92 (3H, s, H~3~-18); selected ^1^H NMR (CDCl~3~, 400 MHz) of **1b**: δ 7.41−7.53 (5H, m, Ph), 5.47 (1H, br d, *J* = 5.2 Hz, H-6), 4.89 (1H, m, H-3), 4.76 (1H, s, H-28a), 4.70 (1H, s, H-28b), 4.41 (1H, m, H-16), 4.06 (1H, m, H-11), 3.57 (3H, s, O*Me*), 2.65 (1H, br d, *J* = 13.6 Hz, H-1a), 2.37 (1H, m, H-4a), 1.77 (1H, m, H-2a), 1.17 (3H, s, H~3~-19), 1.03 (6H, d, *J* = 7.2 Hz, H~3~-26 and 27), 0.92 (3H, s, H~3~-18).

3.5. Determination of Sugar Configuration
-----------------------------------------

Authentic samples of [D]{.smallcaps}-fucose and [L]{.smallcaps}-cysteine methyl ester hydrochloride (each 0.5 mg) were dissolved in pyridine (0.1 mL) and heated at 60 °C for 1 h. To this mixture was added *o*-tolylisothiocyanate (0.5 mg in 0.1 mL pyridine) and heated at 60 °C for additional 1 h. The reaction mixture was directly analyzed by reversed-phase HPLC (Mightysil RP-18 GP column; 4.6 × 250 nm; 25% CH~3~CN in 50 mM H~3~PO~4~; 0.8 mL/min; 35 °C) and detected at 250 nm to give the retention time of the *o*-tolylthiocarbamate of sugar. The retention of the *o*-tolylthiocarbamate derived from [L]{.smallcaps}-fucose, [L]{.smallcaps}-cysteine methyl ester, and *o*-tolylisothiocyanate was obtained by the same manner.

A solution of the glycoside (0.4 mg for each) in 0.6 M HCl/dioxane (1:1 v/v, 0.2 mL) was heated at 80 °C for 24 h. After cooling, the solution was neutralized with Amberlite IRA-400, and the resin was removed by filtration. The filtrate was extracted with EtOAc. The aqueous layer was dried *in vacuo* and the afforded residue was dissolved in pyridine (0.1 mL) containing [L]{.smallcaps}-cysteine methyl ester (0.5 mg), followed by heating at 60 °C for 1 h. A 0.1 mL solution of *o*-tolylisothiocyanate (0.5 mg) in pyridine was added to the mixture, which was heated at 60 °C for additional 1 h, to yield the corresponding *o*-tolylthiocarbamate derivative. Reverse phase HPLC analysis of the *o*-tolylthiocarbamate derivatives derived from the hydrolytes of the glycosides **2**--**5** showed peaks at 28.2, 28.0, 28.1, and 27.9 min, respectively, while the *t*~R~ values for standard [L]{.smallcaps}-fucose and [D]{.smallcaps}-fucose derivatives were observed at 28.0 and 25.4 min, respectively, suggesting the presence of a [L]{.smallcaps}-fucose residue in **2**--**5**.

3.6. Cytotoxicity Testing
-------------------------

Cell lines were purchased from the American Type Culture Collection (ATCC). Compounds were assayed for cytotoxicity against human liver carcinoma (HepG2 and HepG3), human breast carcinoma (MCF-7 and MDA-MB-231), and human lung carcinoma (A-549) cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method \[[@B19-marinedrugs-10-00439]\]. Freshly trypsinized cell suspensions were seeded in 96-well microtiter plates at densities of 5000--10000 cells per well with tested compounds added from DMSO-diluted stock. After 3 days in culture, attached cells were incubated with MTT (0.5 mg/mL, 1 h) and subsequently dissolved in DMSO. The absorbency at 550 nm was then measured using a microplate reader. The IC~50~ is the concentration of agent that reduced cell growth by 50% under the experimental conditions.

3.7. *In Vitro* Anti-Inflammatory Assay
---------------------------------------

Macrophage (RAW264.7) cell line was purchased from ATCC. In vitro anti-inflammatory activities of tested compounds were measured by examining the inhibition of lipopolysaccharide (LPS) induced upregulation of iNOS and COX-2 proteins in macrophage cells using western blotting analysis \[[@B20-marinedrugs-10-00439],[@B21-marinedrugs-10-00439]\].

4. Conclusions
==============

Prior investigation of the genus *S* *inularia* reported on several steroidal glycosides, however, all of these were found to possess a 24-methylene substituted side chain \[[@B22-marinedrugs-10-00439],[@B23-marinedrugs-10-00439]\]. **5** is the first example of steroidal glycoside with a 23,24-dimethyl substitited side chain from soft coral of the genus *S* *inularia*. Our biological data reveal that 2′-*O*-acetyl-[L]{.smallcaps}-fucose functionality plays an important role toward the inhibition of the pro-inflammatory iNOS. Steroidal glycoside **2** could be a useful anti-inflammatory agent, while steroids **1** and **4** have shown inhibitory activity toward the selected human liver cancer cells.
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